These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35660765)

  • 41. Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Gagné A; Orain M; Ionescu D; Tsao MS; Joubert D; Joubert P
    Lung Cancer; 2020 Aug; 146():276-284. PubMed ID: 32593917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer.
    Haragan A; Parashar P; Bury D; Cross G; Gosney JR
    J Clin Pathol; 2024 Jan; 77(2):140-144. PubMed ID: 38071529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
    Butter R; Hondelink LM; van Elswijk L; Blaauwgeers JLG; Bloemena E; Britstra R; Bulkmans N; van Gulik AL; Monkhorst K; de Rooij MJ; Slavujevic-Letic I; Smit VTHBM; Speel EM; Thunnissen E; von der Thüsen JH; Timens W; van de Vijver MJ; Yick DCY; Zwinderman AH; Cohen D; 't Hart NA; Radonic T
    Lung Cancer; 2022 Apr; 166():143-149. PubMed ID: 35279453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
    Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
    Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
    Front Immunol; 2022; 13():813072. PubMed ID: 35250988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
    Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
    J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology.
    Lin YY; Wang LC; Hsieh YH; Hung YL; Chen YA; Lin YC; Lin YY; Chou TY
    J Transl Med; 2022 Mar; 20(1):131. PubMed ID: 35296339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
    Pagni F; Malapelle U; Doglioni C; Fontanini G; Fraggetta F; Graziano P; Marchetti A; Guerini Rocco E; Pisapia P; Vigliar EV; Buttitta F; Jaconi M; Fusco N; Barberis M; Troncone G
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
    Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
    Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
    Bigras G; Mairs S; Swanson PE; Morel D; Lai R; Izevbaye I
    Appl Immunohistochem Mol Morphol; 2018; 26(10):701-708. PubMed ID: 30095468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
    Kuempers C; van der Linde LIS; Reischl M; Vogel W; Stellmacher F; Reck M; Heigener D; Rabe KF; Kirfel J; Perner S; Welker L
    Virchows Arch; 2020 Feb; 476(2):261-271. PubMed ID: 31392467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
    Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
    Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
    Park S; Ock CY; Kim H; Pereira S; Park S; Ma M; Choi S; Kim S; Shin S; Aum BJ; Paeng K; Yoo D; Cha H; Park S; Suh KJ; Jung HA; Kim SH; Kim YJ; Sun JM; Chung JH; Ahn JS; Ahn MJ; Lee JS; Park K; Song SY; Bang YJ; Choi YL; Mok TS; Lee SH
    J Clin Oncol; 2022 Jun; 40(17):1916-1928. PubMed ID: 35271299
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.
    Wang X; Wang L; Bu H; Zhang N; Yue M; Jia Z; Cai L; He J; Wang Y; Xu X; Li S; Xiao K; Yan K; Tian K; Han X; Huang J; Yao J; Liu Y
    NPJ Breast Cancer; 2021 May; 7(1):61. PubMed ID: 34039982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
    Tancoš V; Grendár M; Farkašová A; Huťka Z; Kviatkovská Z; Plank L
    Klin Onkol; 2020; 33(1):55-65. PubMed ID: 32075390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.